Arbital Health’s $31 million Series B round was led by Valtruis and included participation from existing investors Transformation Capital, Shaper Capital and Healthy Ventures. The post Arbital Health Raises $31M to Support Value-Based Care Contracting appeared first on MedCity News.
This issue brief provides an update on the latest trends in kindergarten children’s routine vaccination and exemption rates. Over three-quarters (39) of states had measles, mumps, rubella (MMR)vaccination rates below the “target” rate of 95% for the 2024-2025 school year.
One CIO discusses the process of adopting a new EHR system at their organization
National Endowment for the Humanities funds Center for Humanities-based Health AI Innovation
Providence researchers discuss their recently published results on the impact of ambient clinical intelligence on documentation workload
A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing development of the oral drug in diabetic peripheral neuropathy. The post Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study appeared first on…
As part of the 2024 KFF Women’s Health Survey, a nationally representative sample of 1,191 men ages 18 to 64 were surveyed on a broad range of health issues. This data note highlights their responses to their experiences, knowledge, and perspectives about vasectomy services.
This fact sheet explains the types of permanent contraception or sterilization procedures available, reviews private insurance and Medicaid coverage policy, and discusses issues that affect availability in the U.S.
A small number of innovative health systems and plans have incorporated technology and cultural integrations that recognize the comprehensive cognitive, social, and environmental drivers and barriers that influence member behaviors. However, progress has been slow — here are three key areas where behavioral science can significantly impact plans and their members. The post Why Behavioral…
Payers will often look to disease analogs when making pricing and coverage decisions. These disease analogs can inform the level of rebates, need for prior authorization/utilization management, and the drug’s cost sharing tier. Traditionally, however, disease analogs are selected on an ad hoc basis. In a recent JMCP paper titled “A structured approach for identifying…